Epidermal and transforming growth factor alpha in patients with breast tumours. View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

1989-04

AUTHORS

H. Gregory, C. E. Thomas, I. R. Willshire, J. A. Young, H. Anderson, A. Baildam, A. Howell

ABSTRACT

Measurements of transforming growth factor alpha (TGF-alpha) in cancer patients have produced variable results. We have now used a specific radioimmunoassay (RIA) and a mitogenic assay to evaluate TGF-alpha content of tumour and urine samples separated by an analytical HPLC system. Urine samples from patients with breast tumours and from age matched controls gave TGF-alpha amounts ranging from 0 to 61.5 ng 24 h-1 compared to urogastrone epidermal growth factor figures of 3.0-26.2 micrograms 24 h-1. The quantities of TGF-alpha in patient and control groups were not significantly different. The majority of breast tumour extracts contained mitogenic material eluting from the HPLC system at the TGF-alpha calibration point. Measurement by RIA of combined samples from each group showed that steroid receptor positive tumours had a mean figure of 14.8 ng g-1 tissue and steroid receptor negative 7.4 ng g-1. Receptor positive tumours from patients treated with an antioestrogen, tamoxifen citrate (Nolvadex), had 0.16 ng g-1. Thus TGF-alpha is found in tumours as a biologically active entity and in quantities sufficient to promote cell division. In addition the observation that tamoxifen causes a significant reduction in the content of TGF-alpha may be an additional beneficial action. More... »

PAGES

605-609

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/bjc.1989.122

DOI

http://dx.doi.org/10.1038/bjc.1989.122

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1005779164

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/2785399


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Breast Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Chromatography, High Pressure Liquid", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Epidermal Growth Factor", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Transforming Growth Factors", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Bioscience I Department, ICI Pharmaceuticals, Macclesfield, Cheshire, UK.", 
          "id": "http://www.grid.ac/institutes/grid.417815.e", 
          "name": [
            "Bioscience I Department, ICI Pharmaceuticals, Macclesfield, Cheshire, UK."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gregory", 
        "givenName": "H.", 
        "id": "sg:person.01166603761.61", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01166603761.61"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Bioscience I Department, ICI Pharmaceuticals, Macclesfield, Cheshire, UK.", 
          "id": "http://www.grid.ac/institutes/grid.417815.e", 
          "name": [
            "Bioscience I Department, ICI Pharmaceuticals, Macclesfield, Cheshire, UK."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Thomas", 
        "givenName": "C. E.", 
        "id": "sg:person.01142734345.43", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01142734345.43"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Bioscience I Department, ICI Pharmaceuticals, Macclesfield, Cheshire, UK.", 
          "id": "http://www.grid.ac/institutes/grid.417815.e", 
          "name": [
            "Bioscience I Department, ICI Pharmaceuticals, Macclesfield, Cheshire, UK."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Willshire", 
        "givenName": "I. R.", 
        "id": "sg:person.01257162745.02", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01257162745.02"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Bioscience I Department, ICI Pharmaceuticals, Macclesfield, Cheshire, UK.", 
          "id": "http://www.grid.ac/institutes/grid.417815.e", 
          "name": [
            "Bioscience I Department, ICI Pharmaceuticals, Macclesfield, Cheshire, UK."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Young", 
        "givenName": "J. A.", 
        "id": "sg:person.01314460477.31", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01314460477.31"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Bioscience I Department, ICI Pharmaceuticals, Macclesfield, Cheshire, UK.", 
          "id": "http://www.grid.ac/institutes/grid.417815.e", 
          "name": [
            "Bioscience I Department, ICI Pharmaceuticals, Macclesfield, Cheshire, UK."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Anderson", 
        "givenName": "H.", 
        "id": "sg:person.0712601561.50", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0712601561.50"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Bioscience I Department, ICI Pharmaceuticals, Macclesfield, Cheshire, UK.", 
          "id": "http://www.grid.ac/institutes/grid.417815.e", 
          "name": [
            "Bioscience I Department, ICI Pharmaceuticals, Macclesfield, Cheshire, UK."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Baildam", 
        "givenName": "A.", 
        "id": "sg:person.0676001440.34", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0676001440.34"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Bioscience I Department, ICI Pharmaceuticals, Macclesfield, Cheshire, UK.", 
          "id": "http://www.grid.ac/institutes/grid.417815.e", 
          "name": [
            "Bioscience I Department, ICI Pharmaceuticals, Macclesfield, Cheshire, UK."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Howell", 
        "givenName": "A.", 
        "id": "sg:person.01005610111.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01005610111.35"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/313745a0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010441557", 
          "https://doi.org/10.1038/313745a0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/257325a0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022992282", 
          "https://doi.org/10.1038/257325a0"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "1989-04", 
    "datePublishedReg": "1989-04-01", 
    "description": "Measurements of transforming growth factor alpha (TGF-alpha) in cancer patients have produced variable results. We have now used a specific radioimmunoassay (RIA) and a mitogenic assay to evaluate TGF-alpha content of tumour and urine samples separated by an analytical HPLC system. Urine samples from patients with breast tumours and from age matched controls gave TGF-alpha amounts ranging from 0 to 61.5 ng 24 h-1 compared to urogastrone epidermal growth factor figures of 3.0-26.2 micrograms 24 h-1. The quantities of TGF-alpha in patient and control groups were not significantly different. The majority of breast tumour extracts contained mitogenic material eluting from the HPLC system at the TGF-alpha calibration point. Measurement by RIA of combined samples from each group showed that steroid receptor positive tumours had a mean figure of 14.8 ng g-1 tissue and steroid receptor negative 7.4 ng g-1. Receptor positive tumours from patients treated with an antioestrogen, tamoxifen citrate (Nolvadex), had 0.16 ng g-1. Thus TGF-alpha is found in tumours as a biologically active entity and in quantities sufficient to promote cell division. In addition the observation that tamoxifen causes a significant reduction in the content of TGF-alpha may be an additional beneficial action.", 
    "genre": "article", 
    "id": "sg:pub.10.1038/bjc.1989.122", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1017082", 
        "issn": [
          "0007-0920", 
          "1532-1827"
        ], 
        "name": "British Journal of Cancer", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "59"
      }
    ], 
    "keywords": [
      "receptor-positive tumors", 
      "growth factor alpha", 
      "positive tumors", 
      "factor alpha", 
      "TGF-alpha", 
      "breast tumors", 
      "steroid receptor-positive tumors", 
      "TGF-alpha content", 
      "micrograms 24 h", 
      "additional beneficial actions", 
      "urine samples", 
      "breast tumor extracts", 
      "cancer patients", 
      "tumor extracts", 
      "specific radioimmunoassay", 
      "patients", 
      "beneficial actions", 
      "control group", 
      "tumors", 
      "steroid receptors", 
      "tamoxifen citrate", 
      "mitogenic material", 
      "mitogenic assays", 
      "radioimmunoassay", 
      "significant reduction", 
      "variable results", 
      "alpha", 
      "mean figure", 
      "antioestrogens", 
      "group", 
      "HPLC system", 
      "receptors", 
      "age", 
      "tissue", 
      "assays", 
      "majority", 
      "samples", 
      "extract", 
      "citrate", 
      "control", 
      "entities", 
      "action", 
      "reduction", 
      "cell division", 
      "active entities", 
      "addition", 
      "measurements", 
      "content", 
      "results", 
      "figures", 
      "observations", 
      "amount", 
      "system", 
      "division", 
      "point", 
      "analytical HPLC system", 
      "quantity", 
      "materials", 
      "calibration points", 
      "TGF-alpha amounts", 
      "urogastrone epidermal growth factor figures", 
      "epidermal growth factor figures", 
      "growth factor figures", 
      "factor figures", 
      "TGF-alpha calibration point"
    ], 
    "name": "Epidermal and transforming growth factor alpha in patients with breast tumours.", 
    "pagination": "605-609", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1005779164"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/bjc.1989.122"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "2785399"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/bjc.1989.122", 
      "https://app.dimensions.ai/details/publication/pub.1005779164"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-01-01T18:03", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_196.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1038/bjc.1989.122"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/bjc.1989.122'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/bjc.1989.122'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/bjc.1989.122'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/bjc.1989.122'


 

This table displays all metadata directly associated to this object as RDF triples.

197 TRIPLES      22 PREDICATES      99 URIs      89 LITERALS      12 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/bjc.1989.122 schema:about N47f75568ee944dada6322356f88f4dbb
2 N4be1bf5fcdb94e4d8c1674a815a2d497
3 N6a349e866316482bae58eda1c0eb66cb
4 N90ae3070b35b412bac784e70c1fa7f2c
5 Nce68bba2303b476fb27ebcc4af8e023d
6 anzsrc-for:11
7 anzsrc-for:1112
8 schema:author N726678db70f44143b9c13e32a1a0f781
9 schema:citation sg:pub.10.1038/257325a0
10 sg:pub.10.1038/313745a0
11 schema:datePublished 1989-04
12 schema:datePublishedReg 1989-04-01
13 schema:description Measurements of transforming growth factor alpha (TGF-alpha) in cancer patients have produced variable results. We have now used a specific radioimmunoassay (RIA) and a mitogenic assay to evaluate TGF-alpha content of tumour and urine samples separated by an analytical HPLC system. Urine samples from patients with breast tumours and from age matched controls gave TGF-alpha amounts ranging from 0 to 61.5 ng 24 h-1 compared to urogastrone epidermal growth factor figures of 3.0-26.2 micrograms 24 h-1. The quantities of TGF-alpha in patient and control groups were not significantly different. The majority of breast tumour extracts contained mitogenic material eluting from the HPLC system at the TGF-alpha calibration point. Measurement by RIA of combined samples from each group showed that steroid receptor positive tumours had a mean figure of 14.8 ng g-1 tissue and steroid receptor negative 7.4 ng g-1. Receptor positive tumours from patients treated with an antioestrogen, tamoxifen citrate (Nolvadex), had 0.16 ng g-1. Thus TGF-alpha is found in tumours as a biologically active entity and in quantities sufficient to promote cell division. In addition the observation that tamoxifen causes a significant reduction in the content of TGF-alpha may be an additional beneficial action.
14 schema:genre article
15 schema:inLanguage en
16 schema:isAccessibleForFree true
17 schema:isPartOf N221c9d76407d41789152d8bf6992f37e
18 N5ad18fc289e04c829724c54463a276fe
19 sg:journal.1017082
20 schema:keywords HPLC system
21 TGF-alpha
22 TGF-alpha amounts
23 TGF-alpha calibration point
24 TGF-alpha content
25 action
26 active entities
27 addition
28 additional beneficial actions
29 age
30 alpha
31 amount
32 analytical HPLC system
33 antioestrogens
34 assays
35 beneficial actions
36 breast tumor extracts
37 breast tumors
38 calibration points
39 cancer patients
40 cell division
41 citrate
42 content
43 control
44 control group
45 division
46 entities
47 epidermal growth factor figures
48 extract
49 factor alpha
50 factor figures
51 figures
52 group
53 growth factor alpha
54 growth factor figures
55 majority
56 materials
57 mean figure
58 measurements
59 micrograms 24 h
60 mitogenic assays
61 mitogenic material
62 observations
63 patients
64 point
65 positive tumors
66 quantity
67 radioimmunoassay
68 receptor-positive tumors
69 receptors
70 reduction
71 results
72 samples
73 significant reduction
74 specific radioimmunoassay
75 steroid receptor-positive tumors
76 steroid receptors
77 system
78 tamoxifen citrate
79 tissue
80 tumor extracts
81 tumors
82 urine samples
83 urogastrone epidermal growth factor figures
84 variable results
85 schema:name Epidermal and transforming growth factor alpha in patients with breast tumours.
86 schema:pagination 605-609
87 schema:productId Na5b24f39878b46c68258e1ee5e5df801
88 Ne2a573945a5743aba5cbd518c668439e
89 Nf9e0715f00884d128578c059455a2268
90 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005779164
91 https://doi.org/10.1038/bjc.1989.122
92 schema:sdDatePublished 2022-01-01T18:03
93 schema:sdLicense https://scigraph.springernature.com/explorer/license/
94 schema:sdPublisher N3ad79807daa0465ca5b25dd8bd01610d
95 schema:url https://doi.org/10.1038/bjc.1989.122
96 sgo:license sg:explorer/license/
97 sgo:sdDataset articles
98 rdf:type schema:ScholarlyArticle
99 N18c46ab7e2f94617b12f04d3bd123e26 rdf:first sg:person.01314460477.31
100 rdf:rest Na1e4ce2c56524cf980f955723404af2e
101 N221c9d76407d41789152d8bf6992f37e schema:volumeNumber 59
102 rdf:type schema:PublicationVolume
103 N3ad79807daa0465ca5b25dd8bd01610d schema:name Springer Nature - SN SciGraph project
104 rdf:type schema:Organization
105 N47670f91a8e44708a042b2b15b5e6930 rdf:first sg:person.01257162745.02
106 rdf:rest N18c46ab7e2f94617b12f04d3bd123e26
107 N47f75568ee944dada6322356f88f4dbb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
108 schema:name Epidermal Growth Factor
109 rdf:type schema:DefinedTerm
110 N4be1bf5fcdb94e4d8c1674a815a2d497 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
111 schema:name Chromatography, High Pressure Liquid
112 rdf:type schema:DefinedTerm
113 N50d22b2b393c491da2cf1a44e1d20a3e rdf:first sg:person.01005610111.35
114 rdf:rest rdf:nil
115 N5ad18fc289e04c829724c54463a276fe schema:issueNumber 4
116 rdf:type schema:PublicationIssue
117 N6a349e866316482bae58eda1c0eb66cb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Transforming Growth Factors
119 rdf:type schema:DefinedTerm
120 N726678db70f44143b9c13e32a1a0f781 rdf:first sg:person.01166603761.61
121 rdf:rest Nfbc965c3d8de49b183bffd9d715a769c
122 N8fff758fae6e435aac8d8c66d67e519e rdf:first sg:person.0676001440.34
123 rdf:rest N50d22b2b393c491da2cf1a44e1d20a3e
124 N90ae3070b35b412bac784e70c1fa7f2c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
125 schema:name Breast Neoplasms
126 rdf:type schema:DefinedTerm
127 Na1e4ce2c56524cf980f955723404af2e rdf:first sg:person.0712601561.50
128 rdf:rest N8fff758fae6e435aac8d8c66d67e519e
129 Na5b24f39878b46c68258e1ee5e5df801 schema:name dimensions_id
130 schema:value pub.1005779164
131 rdf:type schema:PropertyValue
132 Nce68bba2303b476fb27ebcc4af8e023d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Humans
134 rdf:type schema:DefinedTerm
135 Ne2a573945a5743aba5cbd518c668439e schema:name pubmed_id
136 schema:value 2785399
137 rdf:type schema:PropertyValue
138 Nf9e0715f00884d128578c059455a2268 schema:name doi
139 schema:value 10.1038/bjc.1989.122
140 rdf:type schema:PropertyValue
141 Nfbc965c3d8de49b183bffd9d715a769c rdf:first sg:person.01142734345.43
142 rdf:rest N47670f91a8e44708a042b2b15b5e6930
143 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
144 schema:name Medical and Health Sciences
145 rdf:type schema:DefinedTerm
146 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
147 schema:name Oncology and Carcinogenesis
148 rdf:type schema:DefinedTerm
149 sg:journal.1017082 schema:issn 0007-0920
150 1532-1827
151 schema:name British Journal of Cancer
152 schema:publisher Springer Nature
153 rdf:type schema:Periodical
154 sg:person.01005610111.35 schema:affiliation grid-institutes:grid.417815.e
155 schema:familyName Howell
156 schema:givenName A.
157 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01005610111.35
158 rdf:type schema:Person
159 sg:person.01142734345.43 schema:affiliation grid-institutes:grid.417815.e
160 schema:familyName Thomas
161 schema:givenName C. E.
162 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01142734345.43
163 rdf:type schema:Person
164 sg:person.01166603761.61 schema:affiliation grid-institutes:grid.417815.e
165 schema:familyName Gregory
166 schema:givenName H.
167 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01166603761.61
168 rdf:type schema:Person
169 sg:person.01257162745.02 schema:affiliation grid-institutes:grid.417815.e
170 schema:familyName Willshire
171 schema:givenName I. R.
172 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01257162745.02
173 rdf:type schema:Person
174 sg:person.01314460477.31 schema:affiliation grid-institutes:grid.417815.e
175 schema:familyName Young
176 schema:givenName J. A.
177 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01314460477.31
178 rdf:type schema:Person
179 sg:person.0676001440.34 schema:affiliation grid-institutes:grid.417815.e
180 schema:familyName Baildam
181 schema:givenName A.
182 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0676001440.34
183 rdf:type schema:Person
184 sg:person.0712601561.50 schema:affiliation grid-institutes:grid.417815.e
185 schema:familyName Anderson
186 schema:givenName H.
187 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0712601561.50
188 rdf:type schema:Person
189 sg:pub.10.1038/257325a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022992282
190 https://doi.org/10.1038/257325a0
191 rdf:type schema:CreativeWork
192 sg:pub.10.1038/313745a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010441557
193 https://doi.org/10.1038/313745a0
194 rdf:type schema:CreativeWork
195 grid-institutes:grid.417815.e schema:alternateName Bioscience I Department, ICI Pharmaceuticals, Macclesfield, Cheshire, UK.
196 schema:name Bioscience I Department, ICI Pharmaceuticals, Macclesfield, Cheshire, UK.
197 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...